Group 1: Market Outlook and Investment Strategies - KKR's Head of Global Macro and Asset Allocation, Henry McVey, anticipates a strong growth year in 2026, supported by robust earnings despite current geopolitical tensions affecting logistics and supply chains [1] - McVey emphasizes the importance of diversifying investments into international markets such as Japan and India, as well as moving into real assets like infrastructure and real estate, which are expected to perform well in nominal GDP [2] - Current AI spending is approximately 5% of the US GDP, compared to 7% during the housing crisis, indicating a shift in investment focus towards companies with solid balance sheets rather than speculative options [2] Group 2: Company Highlights - Novo Nordisk A/S announced a €432 million (DKK 3.2 billion) investment in its Monksland facility in Ireland to enhance production of oral GLP-1 treatments, aiming to serve international markets outside the US [7][8] - The investment will retrofit the existing plant and is expected to create up to 500 jobs during construction, with a focus on high-quality, sustainable oral treatments [9] - JPMorgan Chase & Co. appointed Stephanie Davis and Sean Flynn to key positions in its Asset Management division, aiming to expand its private market product offerings and grow its advisory team [11][12][13]

月度创新药前沿跟踪 2026 年 2 月 [Table_Industry] 医药 股票研究 /[Table_Date] 2026.03.05 医药《持续推荐创新药械产业链》2026.03.02 医药《从靶点到管线，FXI 引领抗凝产业新变 革》2026.02.25 医药《医疗设备招采规模高基数影响部分回落， 关注手术机器人市场机遇》2026.02.09 医药《高景气延续，持续推荐创新药械产业链》 2026.02.08 医药《国内创新药景气度强复苏，看好内需 CRO 业绩持续改善》2026.02.06 股 票 研 究 行 业 跟 踪 报 告 证 券 研 究 报 告 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 余文心(分析师) | 021-38676666 | yuwenxin@gtht.com | S0880525040111 | | 余克清(分析师) | 010-56760093 | yukeqing@gtht.com | S0880525120002 | | 陈铭(分析师) | 021-23219164 | chenm ...

股票研究 /[Table_Date] 2026.03.05 月度创新药前沿跟踪 2026 年 2 月 [Table_Industry] 医药 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 余文心(分析师) | 021-38676666 | yuwenxin@gtht.com | S0880525040111 | | 余克清(分析师) | 010-56760093 | yukeqing@gtht.com | S0880525120002 | | 陈铭(分析师) | 021-23219164 | chenming7@gtht.com | S0880525100004 | | 廖博闻(研究助理) | 021-23187268 | liaobowen@gtht.com | S0880125042239 | 本报告导读： 本报告为全球创新药前沿的月度跟踪报告，梳理和提示了相关前沿领域的进展和投 资机会。 投资要点： [Table_Invest] 评级： 增持 [Table_Report] 相关报告 医药《持续推荐创新药械产业链》20 ...

By Nqobile Dludla JOHANNESBURG, March 4 (Reuters) - Aspen Pharmacare aims to secure sub‑Saharan African approval for Eli Lilly's blockbuster weight‑loss drug Mounjaro ‌as early as this year, its CEO said on Wednesday, capitalising ‌on soaring regional demand for obesity treatments. South Africa-based Aspen’s push to register Mounjaro across the ​region signals its bid to become a key manufacturing and distribution partner for global drugmakers eyeing one of the last major untapped markets for GLP‑1 weigh ...

Denmark’s economy is poised to expand at the fastest pace in the Nordic region this year, even as pharmaceutical giant Novo Nordisk grapples with slowing sales, according to the country’s largest lender https://t.co/Ci3h63C9v5 ...

US FDA warns Novo for second time about misleading drug advertising | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]A box of Ozempic and contents sit on a table in Dudley, North Tyneside, Britain, October 31, 2023. REUTERS/Lee Smith [Purchase Licensing Rights, opens new tab]- Companies[Novo Nordisk A/S]Follow[U.S. Food and Drug Administration]FollowMarch 3 (Reuters) - The U.S. Food and Drug Administration has told Novo Nordisk [(NO ...

整理 | GLP1减重宝典内容团队 2026年3月3日，诺和诺德宣布其司美格鲁肽注射液的新适应症在中国已提交上市申请，并拟纳入优先审评。这一新适应症旨在治疗伴有中至重 度肝纤维化的代谢相关脂肪性肝炎（MASH）患者，特别是针对F2-F3期的非肝硬化成人患者。 司美格鲁肽的全球影响力 司美格鲁肽作为诺和诺德的旗舰药物，早在2025年8月已获得美国FDA批准，用于治疗伴有中度到重度肝纤维化的非肝硬化MASH患者，且要 求联合低热量饮食和增加体力活动。此次中国的申报，是基于ESSENCE临床试验的部分结果。该试验评估了每周一次注射2.4mg司美格鲁肽的 疗效，结果显示，司美格鲁肽在改善肝纤维化和脂肪性肝炎消退方面，均表现出优于安慰剂的统计学显著性。 临床试验结果 ESSENCE试验的第一阶段结果表明，使用司美格鲁肽的患者在改善肝纤维化和消退脂肪性肝炎方面，达到了以下临床指标： 在第72周时，36.8%的患者实现了"肝纤维化改善且无脂肪性肝炎恶化"，而安慰剂组仅为22.4%。 62.9%的患者达到了"脂肪性肝炎消退且无肝纤维化恶化"的效果，而安慰剂组为34.3%。 作为诺和诺德的明星药物，司美格鲁肽的销售表现十分亮眼 ...

The Novo Nordisk ( NVO ) ( NONOF ) story keeps getting hammered by the markets. Every time it goes down by 10-20%, it seems the valuations have hit rock bottom, only for more downside to emerge. The latest roundI am a stock analyst with over 20 years of experience in quantitative research, financial modeling, and risk management. My focus is on equity valuation, market trends, and portfolio optimization to uncover high-growth investment opportunities. As a former Vice President at Barclays, I led teams in m ...

Novo Nordisk has invested €432m ($501m) to upgrade its facility in Ireland to ensure the drugmaker can meet the anticipated high demand for oral weight loss drugs. Novo’s site in Monksland, Athlone, is one of 16 facilities the company has across the world. The expansion of the 45-acre tabletting facility is expected to be completed by 2028, though construction has already begun. The site’s existing 260 employees will focus on delivering oral glucagon-like peptide-1 receptor agonists (GLP-1RAs). The Dani ...

Company Strategy - Roche aims for a double-digit market share in the weight loss market, seeking to close the gap with its competitor Novo Nordisk [1] - The CEO of Roche, Thomas Schinecker, expressed the expectation to be among the top three players in the market at the very least [1]